D-tryptophan from probiotic bacteria influences the gut microbiome and allergic airway disease

Kepert, Inge; Fonseca, Juliano; Müller, Constanze; Milger, Katrin; Hochwind, Kerstin; Kostrić, Matea; Fedoseeva, Maria; Ohnmacht, Caspar; Dehmel, Stefan; Nathan, Petra; Bartel, Sabine; Eickelberg, Oliver; Schloter, Michael; Hartmann, Anton; Schmitt‐Kopplin, Philippe; Krauss‐Etschmann, Susanne

doi:10.1016/j.jaci.2016.09.003

Cited by 128 publications

(102 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent clinical data indicates that indoximod safely heightens the efficacy of anti-PD1 in melanoma patients [116], consistent with preclinical data [117], suggesting that mTORC1 restoration may be a sufficient cause of the antitumor effects of IDO1 blockade [116]. D-amino acids are used for signaling by gut bacteria and the potential interface of IDO1 with the gut microbiome is intriguing to consider in light of D-Trp and its mimetic indoximod as possible PAMP molecules [118, 119]. Further mechanistic investigations of indoximod might yield important new therapeutic directions.…”

Section: Therapeutic Approaches To Block Ido Functionmentioning

confidence: 68%

Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive ‘Cold’ Tumors ‘Hot’

Prendergast¹,

Mondal²,

Dey³

et al. 2018

Trends in Cancer

138

116

View full text Add to dashboard Cite

We discuss how small molecule inhibitors of the tryptophan catabolic enzyme indoleamine 2,3-dioxygenase (IDOi) represent a vanguard of new immunometabolic adjuvants to safely enhance the efficacy of cancer immunotherapy, radiotherapy or 'immunogenic' chemotherapy by leveraging responses to tumor neoantigens. IDO activation in cancer supports inflammatory processes that IDOi can re-program to help clear tumors by blunting tumor neovascularization and restoring immunosurveillance. Studies of regulatory and effector pathways illuminate IDO as an inflammatory modifier. Recent work suggests that coordinate targeting of the Trp catabolic enzymes TDO and IDO2 may also safely broaden efficacy. Understanding IDOi as adjuvants to turn immunologically 'cold' tumors 'hot' can seed new concepts in how to improve the efficacy of cancer therapy while limiting its collateral damage.

show abstract

Section: Therapeutic Approaches To Block Ido Functionmentioning

confidence: 68%

Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive ‘Cold’ Tumors ‘Hot’

Prendergast¹,

Mondal²,

Dey³

et al. 2018

Trends in Cancer

138

116

View full text Add to dashboard Cite

show abstract

“…Besides SCFAs, other microbial metabolites play a key role in host immune modulation and decreased inflammation [reviewed in]. For instance, D‐tryptophan has immunomodulatory properties and was identified as the bioactive substance produced by probiotic Lactobacillus rhamnosus GG (LGG) that decreased airway inflammation and Th2 responses in mice . Polyunsaturated fatty acids (PUFAs) have also been associated with decreased asthma risk.…”

Section: Microbiome Innate Immunity and Asthma Protectionmentioning

confidence: 99%

The role of innate immunity in asthma development and protection: Lessons from the environment

Pivniouk

Gimenes-Júnior

Honeker

et al. 2020

Clin Experimental Allergy

View full text Add to dashboard Cite

Asthma, a complex, chronic disease characterized by airway inflammation, hyperresponsiveness and remodelling, affects over 300 million people worldwide. While the disease is typically associated with exaggerated allergen‐induced type 2 immune responses, these responses are strongly influenced by environmental exposures that stimulate innate immune pathways capable of promoting or protecting from asthma. The dual role played by innate immunity in asthma pathogenesis offers multiple opportunities for both research and clinical interventions and is the subject of this review.

show abstract

“…Additionally, the benefits of pre- or probiotics to promote a healthy growth promoting lung microbiome should be investigated, and in particular the presence of Lactobacilli. d -Tryptophane was recently identified as a potent probiotic that could ameliorate allergic airway inflammation in a mouse model of allergic airway disease, and may therefore also be of interest in the setting of BPD (166). One possible way to achieve the same effect as tryptophane catabolites may be through the proton pump inhibitor omeprazole, which induces detoxification enzyme cytochrome P540 (CYP)1A1 possibly through an AhR-mediated process (167).…”

Section: Current Understanding Of Bpd Pathophysiology New Pathophysimentioning

confidence: 99%

The Future of Bronchopulmonary Dysplasia: Emerging Pathophysiological Concepts and Potential New Avenues of Treatment

Collins¹,

Tibboel²,

Kleer³

et al. 2017

Front. Med.

View full text Add to dashboard Cite

Yearly more than 15 million babies are born premature (<37 weeks gestational age), accounting for more than 1 in 10 births worldwide. Lung injury caused by maternal chorioamnionitis or preeclampsia, postnatal ventilation, hyperoxia, or inflammation can lead to the development of bronchopulmonary dysplasia (BPD), one of the most common adverse outcomes in these preterm neonates. BPD patients have an arrest in alveolar and microvascular development and more frequently develop asthma and early-onset emphysema as they age. Understanding how the alveoli develop, and repair, and regenerate after injury is critical for the development of therapies, as unfortunately there is still no cure for BPD. In this review, we aim to provide an overview of emerging new concepts in the understanding of perinatal lung development and injury from a molecular and cellular point of view and how this is paving the way for new therapeutic options to prevent or treat BPD, as well as a reflection on current treatment procedures.

show abstract

D-tryptophan from probiotic bacteria influences the gut microbiome and allergic airway disease

Abstract: D-tryptophan is a newly identified product from probiotic bacteria. Our findings support the concept that defined bacterial products can be exploited in novel preventative strategies for chronic immune diseases.

Cited by 128 publications

References 60 publications

Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive ‘Cold’ Tumors ‘Hot’

Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive ‘Cold’ Tumors ‘Hot’

The role of innate immunity in asthma development and protection: Lessons from the environment

The Future of Bronchopulmonary Dysplasia: Emerging Pathophysiological Concepts and Potential New Avenues of Treatment

Contact Info

Product

Resources

About